Dr. Daniel Von Hoff
The TD2 team is led by Dr. Daniel Von Hoff, Executive Vice President and Director of the Translational Drug Development Division at TGen, and a world-renowned expert in oncology drug development and clinical trial design. Daniel D. Von Hoff, M.D., is currently Physician-in-Chief and Senior Investigator at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona and Clinical Professor of Medicine, University of Arizona Health Sciences Center...> Click here for more

Tess Burleson, C.P.A., M.B.A.
TGen Chief Operating Officer & President, TGen Accelerators . Tess Burleson's role involves oversight of administrative and operational support divisions, development of basic core infrastructure in support of the operation across all TGen organizations, and strategic business ventures...> Click here for more

Stephen Gately, Ph.D.
President & Chief Scientific Officer. Dr. Stephen Gately obtained his Ph.D. from McGill University in the Department of Neurology and Neurosurgery at the Montreal Neurological Institute and Hospital. Thereafter he joined the Department of Medicine, Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine as Research Assistant Professor where his research focused on the identification and development of pharmacologic and endogenous inhibitors of angiogenesis...> Click here for more

Linda Vocila, BSN,RN,OCN,
Director of Clinical Operations. Linda has 20+ years experience as a Clinical Trials Research Nurse in Oncology and is expe­rienced in all phases of clinical research studies. She has played a significant role in the development of major research programs...> Click here for more

Paul M. Gonzales, BSc.
Director, Non-clinical Operations. Paul Gonzales has ten years of experience working in oncology drug development. Paul has been with TD2 for four years working with biotech clients and maturing the non-clinical research department. Paul's vast experience in preclinical oncology models contributes to the design and execution of client's preclinical development plans...> Click here for more

Debbie Snyder, M.B.A., R.T., C.L.S. (N.C.A.)
Vice President, Business Development. Debbie Snyder has over 15 years experience in oncology preclinical and clinical activities and is responsible for operational and business activities to support biopharmaceutical clients. Debbie has been with TGen for over three years building infrastructure, business models and partners to share in the translational mission of TGen...> Click here for more